MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin

@inproceedings{Gherardi2013MYCNmediatedTR,
  title={MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin},
  author={Samuele Gherardi and Emanuele Valli and Daniela Erriquez and Giovanni Perini},
  booktitle={Front. Oncol.},
  year={2013}
}
Neuroblastoma is the most common extra cranial solid tumor in childhood and the most frequently diagnosed neoplasm during the infancy. MYCN amplification and overexpression occur in about 25% of total neuroblastoma cases and this percentage increases at 30% in advanced stage neuroblastoma. So far, MYCN expression profile is still one of the most robust and significant prognostic markers for neuroblastoma outcome. MYCN is a transcription factor that belongs to the family of MYC oncoproteins… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Epigenetic regulation of neuroblastoma development

  • Cell and Tissue Research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 97 REFERENCES

Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2007
VIEW 6 EXCERPTS

Neuroblastoma: biological insights into a clinical enigma

  • Nature Reviews Cancer
  • 2003
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

MYCNmediated transcriptional repression in neuroblastoma: the other side of the coin

S Citation Gherardi, E Valli, D Erriquez, G Perini
  • Front. Oncol. 3:42
  • 2013